Xenon Pharmaceuticals Inc. – Product Pipeline Review – Q2 2011

Document Sample
Xenon Pharmaceuticals Inc. – Product Pipeline Review – Q2 2011
Xenon Pharmaceuticals Inc. – Product Pipeline Review

– Q2 2011

Reference Code: GMDHC1297CDB



Publication Date: JULY 2011









Xenon Pharmaceuticals Inc. – Product Pipeline Review – Q2 2011 GMDHC1297CDB / Published JULY 2011



© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(1)

Xenon Pharmaceuticals Inc. – Product Pipeline Review









Ta b le o f Co n te n ts

Table of Contents 2

List of Tables 4

List of Figures 4

Xenon Pharmaceuticals Inc. Snapshot 5

Xenon Pharmaceuticals Inc. Overview 5

Key Information 5

Key Facts 5

Xenon Pharmaceuticals Inc. – Research and Development Overview 6

Key Therapeutic Areas 6

Xenon Pharmaceuticals Inc. – Pipeline Review 9

Pipeline Products by Stage of Development 9

Pipeline Products – Monotherapy 10

Xenon Pharmaceuticals Inc. – Pipeline Products Glance 11

Xenon Pharmaceuticals Inc. Clinical Stage Pipeline Products 11

Phase II Products/Combination Treatment Modalities 11

Phase I Products/Combination Treatment Modalities 12

Xenon Pharmaceuticals Inc.–Early Stage Pipeline Products 13

Pre-Clinical Products/Combination Treatment Modalities 13

Discovery Products/Combination Treatment Modalities 14

Xenon Pharmaceuticals Inc. – Drug Profiles 15

Topical XEN402 15

Product Description 15

Mechanism of Action 15

R&D Progress 15

XPF-001 16

Product Description 16

Mechanism of Action 16

R&D Progress 16

Oral XEN402 17

Product Description 17

Mechanism of Action 17

R&D Progress 17

XEN403 18

Product Description 18

Mechanism of Action 18

R&D Progress 18

Stearoyl-CoA Desaturase-1 Drug Development Program 19

Product Description 19

Mechanism of Action 19

R&D Progress 19

XEN 401 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

XEN 501 21

Product Description 21









Xenon Pharmaceuticals Inc. – Product Pipeline Review – Q2 2011 GMDHC1297CDB / Published JULY 2011



©Global Markets Direct.. This report is a licensed product and is not to be photocopied Page(2)

Xenon Pharmaceuticals Inc. – Product Pipeline Review







Mechanism of Action 21

R&D Progress 21

Cardiovascular Program 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

Drug For Anemia Of Inflammation 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

Iron Overload Program 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

Xenon Pharmaceuticals Inc. – Pipeline Analysis 25

Xenon Pharmaceuticals Inc. – Pipeline Products by Therapeutic Class 25

Xenon Pharmaceuticals Inc. - Pipeline Products By Target 26

Xenon Pharmaceuticals Inc. – Pipeline Products by Route of Administration 27

Xenon Pharmaceuticals Inc. – Pipeline Products by Molecule Type 28

Xenon Pharmaceuticals Inc. – Recent Pipeline Updates 29

Xenon Pharmaceuticals Inc. - Dormant Projects 30

Xenon Pharmaceuticals Inc. – Locations And Subsidiaries

By registering with docstoc.com you agree to our
privacy policy and terms of service

Successfully added document to cart!

Successfully added document to cart!